H2BC12 and central nervous system cancer: Then, clinical stratification was conducted based on the glioma dataset; in subgroups of primary therapy outcomes PD&SD, primary therapy outcome PR&CR, IDH status: Mut, age < = 40, and age >40, patients with low H2BC12 expression had better survival outcomes than those with highly expressing H2BC12 (Figures 4A–F, p < 0.001).